CN106413712A - 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 - Google Patents
喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 Download PDFInfo
- Publication number
- CN106413712A CN106413712A CN201580026812.6A CN201580026812A CN106413712A CN 106413712 A CN106413712 A CN 106413712A CN 201580026812 A CN201580026812 A CN 201580026812A CN 106413712 A CN106413712 A CN 106413712A
- Authority
- CN
- China
- Prior art keywords
- milligrams
- compound
- pharmaceutically acceptable
- thyroid
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物。具体而言,本发明涉及喹啉衍生物1‑[[[4‑(4‑氟‑2‑甲基‑1H‑吲哚‑5‑基)氧基‑6‑甲氧基喹啉‑7‑基]氧基]甲基]环丙胺用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物。
Description
PCT国内申请,说明书已公开。
Claims (17)
- PCT国内申请,权利要求书已公开。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910645676.9A CN111035640B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
CN201910645272.XA CN111012785B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410249544.1A CN105213394B (zh) | 2014-06-06 | 2014-06-06 | 具有抗肿瘤活性的喹啉衍生物 |
CN2014102495441 | 2014-06-06 | ||
PCT/CN2015/080859 WO2015185011A1 (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910645676.9A Division CN111035640B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
CN201910645272.XA Division CN111012785B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106413712A true CN106413712A (zh) | 2017-02-15 |
CN106413712B CN106413712B (zh) | 2019-08-16 |
Family
ID=54766181
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410249544.1A Active CN105213394B (zh) | 2014-06-06 | 2014-06-06 | 具有抗肿瘤活性的喹啉衍生物 |
CN201580026812.6A Active CN106413712B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 |
CN201910645272.XA Active CN111012785B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
CN201910645676.9A Active CN111035640B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410249544.1A Active CN105213394B (zh) | 2014-06-06 | 2014-06-06 | 具有抗肿瘤活性的喹啉衍生物 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910645272.XA Active CN111012785B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
CN201910645676.9A Active CN111035640B (zh) | 2014-06-06 | 2015-06-05 | 喹啉衍生物用于治疗甲状腺癌的方法和用途 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102490547B1 (zh) |
CN (4) | CN105213394B (zh) |
WO (1) | WO2015185011A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112043831A (zh) * | 2019-06-05 | 2020-12-08 | 正大天晴药业集团股份有限公司 | 用于联合治疗乳腺癌的喹啉类化合物 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105213394B (zh) * | 2014-06-06 | 2019-04-09 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
AU2017205749B2 (en) * | 2016-01-08 | 2021-12-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Use of quinoline derivatives for treating oesophageal cancer and treatment method, pharmaceutical composition and kit thereof |
CN107296811B (zh) * | 2016-04-15 | 2022-12-30 | 正大天晴药业集团股份有限公司 | 一种用于治疗胃癌的喹啉衍生物 |
EP3682883A4 (en) * | 2017-09-15 | 2021-06-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CHINOLINE DERIVATIVE FOR THE TREATMENT OF NEUROENDOCRINE TUMORS |
CN109748904A (zh) * | 2019-01-31 | 2019-05-14 | 正大天晴药业集团股份有限公司 | 喹啉衍生物的结晶 |
CN111714498A (zh) * | 2019-03-20 | 2020-09-29 | 正大天晴药业集团股份有限公司 | 用于治疗卵巢癌的喹啉衍生物 |
AU2020278733A1 (en) * | 2019-05-23 | 2022-01-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Quinoline derivatives for treatment of head and neck cancer |
CN112336726A (zh) * | 2019-08-09 | 2021-02-09 | 正大天晴药业集团股份有限公司 | 治疗结直肠癌的联用药物组合物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063739A1 (en) * | 2003-12-23 | 2005-07-14 | Pfizer Inc. | Novel quinoline derivatives |
WO2008095015A2 (en) * | 2007-01-30 | 2008-08-07 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Method of treating recurrent tumors |
CN101809012A (zh) * | 2007-03-14 | 2010-08-18 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
CN102344438A (zh) * | 2010-08-01 | 2012-02-08 | 江苏正大天晴药业股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
CN105213394A (zh) * | 2014-06-06 | 2016-01-06 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
-
2014
- 2014-06-06 CN CN201410249544.1A patent/CN105213394B/zh active Active
-
2015
- 2015-06-05 CN CN201580026812.6A patent/CN106413712B/zh active Active
- 2015-06-05 CN CN201910645272.XA patent/CN111012785B/zh active Active
- 2015-06-05 WO PCT/CN2015/080859 patent/WO2015185011A1/zh active Application Filing
- 2015-06-05 KR KR1020167034751A patent/KR102490547B1/ko active IP Right Grant
- 2015-06-05 CN CN201910645676.9A patent/CN111035640B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005063739A1 (en) * | 2003-12-23 | 2005-07-14 | Pfizer Inc. | Novel quinoline derivatives |
WO2008095015A2 (en) * | 2007-01-30 | 2008-08-07 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Method of treating recurrent tumors |
CN101809012A (zh) * | 2007-03-14 | 2010-08-18 | 南京爱德程医药科技有限公司 | 作为血管生成抑制剂的螺取代化合物 |
CN102344438A (zh) * | 2010-08-01 | 2012-02-08 | 江苏正大天晴药业股份有限公司 | 喹啉衍生物的结晶及其制备方法 |
CN105213394A (zh) * | 2014-06-06 | 2016-01-06 | 正大天晴药业集团股份有限公司 | 具有抗肿瘤活性的喹啉衍生物 |
Non-Patent Citations (2)
Title |
---|
柴红等: "甲状腺髓样癌靶向治疗新进展", 《上海交通大学学报( 医学版)》 * |
王中和: "《口腔颌面-头颈肿瘤放射治疗学》", 31 August 2013, 上海世界图书出版社公司 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112043831A (zh) * | 2019-06-05 | 2020-12-08 | 正大天晴药业集团股份有限公司 | 用于联合治疗乳腺癌的喹啉类化合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2015185011A1 (zh) | 2015-12-10 |
CN111035640B (zh) | 2024-03-19 |
CN111035640A (zh) | 2020-04-21 |
CN111012785A (zh) | 2020-04-17 |
CN105213394A (zh) | 2016-01-06 |
CN106413712B (zh) | 2019-08-16 |
KR102490547B1 (ko) | 2023-01-18 |
CN111012785B (zh) | 2024-01-30 |
CN105213394B (zh) | 2019-04-09 |
KR20170007789A (ko) | 2017-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106413712B (zh) | 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物 | |
US10183017B2 (en) | Methods and uses of quinoline derivatives in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same | |
CN105311030B (zh) | 用于抗肿瘤的螺取代化合物 | |
CN107001326A (zh) | 抗非小细胞肺癌的喹啉衍生物 | |
CN109069500A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
CN114652723A (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
CN108601778A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
WO2020057536A1 (zh) | 用于治疗脑肿瘤的喹啉衍生物 | |
CN106999485B (zh) | 抗肺鳞癌的喹啉衍生物 | |
CN111110681A (zh) | 喹啉衍生物联合卡培他滨在治疗肝癌的用途 | |
WO2020057539A1 (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
CN102755319A (zh) | 一种含有普拉格雷和卡维地洛的药物组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1231735 Country of ref document: HK |
|
GR01 | Patent grant | ||
GR01 | Patent grant |